Advanced search
Publication Cover
Expert Opinion on Drug Metabolism & Toxicology Volume 1, 2005 - Issue 4
Submit an article Journal homepage
87
Views
5
CrossRef citations to date
0
Altmetric
Review

Recent advances in pharmacokinetic extrapolation from preclinical data to humans

Keith W Ward Bausch & Lomb, Global Preclinical Development, 1400 N. Goodman Street, Rochester, NY 14603, USA. [email protected]
Pages 583-594 | Published online: 30 Nov 2005

Bibliography

  • REICHERT JM: Trends in development and approval times for new therapeutics in the United States. Nat. Rev. Drug Discov. (2003) 2:695–702.
  • KOLA I, LANDIS J: Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov. (2004) 3:711–715.
  • FRANK R, HARGREAVES R: Clinical biomarkers in drug discovery and development. Nat. Rev. Drug Discov. (2003) 2:566–580.
  • VENKATESH S, LIPPER RA: Role of the development scientist in compound lead selection and optimization. J. Pharm. Sci. (2000) 89:145–154.
  • SMITH D, SCHMID E, JONES B: Do drug metabolism and pharmacokinetic departments make any contribution to drug discovery? Clin. Pharmacokinet. (2002) 41:1005–1019.
  • RILEY RJ, KENNA JG: Cellular models for ADMET predictions and evaluation of drug-drug interactions. Curr. Opin. Drug Discov. Devel. (2004) 7:86–99.
  • HOPFGARTNER G, BOURGOGNE E: Quantitative high-throughput analysis of drugs in biological matrices by mass spectrometry. Mass Spectrom. Rev. (2003) 22:195–214.
  • MANO N, GOTO J: Biomedical and biological mass spectrometry. Anal. Sci. (2003) 19:3–14.
  • FERNANDEZ-METZLER CL, KING RC: The emergence and application of technological advances in biotransformation studies. Curr. Top. Med. Chem. (2002) 2:67–76.
  • HUANG S-M: Drug-drug interactions. In: Applications of Pharmacokinetic Principles in Drug Development. R Krishna (Ed.), Kluwer, New York, US (2004):307–331.
  • CALABRESE EJ: Animal extrapolation: an introduction. In: Principles of Animal Extrapolation. Lewis Publishers, Chelsea, MI, USA (1991):1–8.
  • BOXENBAUM H, DILEA C: First-timein- human dose selection: allometric thoughts and perspectives. J. Clin. Pharmacol. (1995) 35:957–966.
  • WHITE RE: High-throughput screening in drug metabolism and pharmacokinetic support of drug discovery. Ann. Rev. Pharmacol. Toxicol. (2000) 40:133–157.
  • SIETSEMA WK: The absolute oral bioavailability of selected drugs. Int. J. Clin. Pharmacol. Ther. Toxicol. (1989) 27:179–211.
  • RITSCHEL WA: In vivo animal models for bioavailability assessment. STP Pharma (1987) 3:125–141.
  • CHIOU WL, JEONG HY, CHUNG SM, WU TC: Evaluation of using dog as an animal model to study the fraction of oral dose absorbed of 43 drugs in humans. Pharm. Res. (2000) 17:135–140.
  • CHIOU WL, BUEHLER PW: Comparison of oral absorption and bioavailability of drugs between monkey and human. Pharm. Res. (2002) 19:868–874.
  • CHIOU WL, BARVE A: Linear correlation of the fraction of oral dose absorbed of 64 drugs between humans and rats. Pharm. Res. (1998) 15:1792–1795.
  • CHIOU WL, MA C, CHUNG SM, JEONG HY: Similarity in the linear and non-linear oral absorption of drugs between human and rat. Int. J. Clin. Pharmacol. Ther. (2000) 38:532–539.
  • WARD KW, NAGILLA R, JOLIVETTE LJ: Comparative evaluation of oral systemic exposure of fifty-six xenobiotics in rat, dog, monkey and humans. Xenobiotica (2005) 35:191–210:
  • WONG H, GROSSMAN SJ, BAI SA et al.: The chimpanzee (Pan troglodytes) as a pharmacokinetic model for selection of drug candidates: model characterization and application. Drug Metab. Dispos. (2004) 32:1359–1369.
  • BANNER M: The use of primates under the Animals (Scientific Procedures) Act (1986): analysis of current trends with particular reference to regulatory toxicology. The Animal Procedures Committee Publications Centre, London, UK (2002).
  • WITKAMP RF, MONSHOUWER M: Pharmacokinetics in vivo and in vitro in swine. Scand. J. Lab. Anim. Sci. (1998) 25(Suppl. 1):45–56.
  • DEDRICK RL: Animal scale-up. J. Pharmacokinet. Biopharm. (1973) 1:435–461.
  • BOXENBAUM H: Interspecies scaling, allometry, physiological time and the ground plan of pharmacokinetics. J. Pharmacokinet. Biopharm. (1982) 10:201–227.
  • BOXENBAUM H: Interspecies pharmacokinetic scaling and the evolutionary-comparative paradigm. Drug Metab. Rev. (1984) 15:1071–1121.
  • BONATE PL, HOWARD D: Critique of prospective allometric scaling: does the emperor have clothes? J. Clin. Pharmacol. (2000) 40:335–340.
  • WARD KW, SMITH BR: A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog and monkey to humans. I. Clearance. Drug Metab. Dispos. (2004) 32:603–611.
  • WARD KW, SMITH BR: A comprehensive quantitative and qualitative evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog and monkey to humans. II. Volume of distribution and mean residence time. Drug Metab. Dispos. (2004) 32:612–619.
  • WARD KW, NAGILLA R: A comprehensive analysis of the role of correction factors in the allometric predictivity of clearance from rat, dog and monkey to human. J. Pharm. Sci. (2004) 93:2522–2534. [Erratum in J. Pharm. Sci. (2005) 94: 231–232]
  • SCHWARTZ S, PATEMAN T: Pre- Clinical Pharmacokinetics. In: A Handbook of Bioanalysis and Drug Metabolism. CRC Press, Boca Raton, FL, USA (2004):113–131.
  • CALDWELL GW, MASUCCI JA, YAN Z, HAGEMAN W: Allometric scaling of pharmacokinetic parameters in drug discovery: Can human CL, Vss, and t1/2 be predicted from in vivo rat data? Eur. J. Drug Metab. Pharmacokinet. (2004) 29:133–143.
  • WARD KW, ERHARDT P, BACHMANN K: Application of simple mathematical expressions to relate the halflives of xenobiotics in rats to values in humans. J. Pharmacol. Toxicol. Methods (2005) 51:57–64.
  • COX KA, WHITE RE, KORFMACHERWA: Rapid determination of pharmacokinetic properties of new chemical entities: in vivo approaches. Comb. Chem. High Throughput Screen. (2002) 5:29–37.
  • GUNARATNA PC, KISSINGER PT, KISSINGER CB, GITZEN JF: An automated blood sampler for simultaneous sampling of systemic blood and brain microdialysates for drug absorption, distribution, metabolism and elimination studies. J. Pharmacol. Toxicol. Methods (2004) 49:57–64.
  • CORCHERO J, GRANVIL CP, AKIYAMA TE et al. : The CYP2D6 humanized mouse: effect of the human CYP2D6 transgene and HNF4à on the disposition of debrisoquine in the mouse. Mol. Pharmacol. (2001) 60:1260–1267.
  • KATOH M, MATSUI T, NAKAJIMA M et al. : Expression of human cytochromes P450 in chimeric mice with humanized liver. Drug Metab. Dispos. (2004) 32:1402–1410.
  • LAPPIN G, GARNER RC: Big physics, small doses: the use of AMS and PET in human microdosing of development drugs. Nat. Rev. Drug Discov. (2003) 2:233–240.
  • WILDING I, GARNER RC: A small dose in time. Good Clinical Practice Journal (2004) 11:2–4.
  • SANDHU P, VOGEL JS, ROSE MJ et al. : Evaluation of microdosing strategies for studies in preclinical drug development: demonstration of linear pharmacokinetics in dogs of a nucleoside analog over a 50-fold dose range. Drug Metab. Dispos. (2004) 32:1254–1259.
  • RANE A, WILKINSON GR, SHAND DG: Prediction of hepatic extraction ratio from in vitro measurement of intrinsic clearance. J. Pharmacol. Exp. Ther. (1977) 200:420–424.
  • ITO K, IWATSUBO T, KANAMITSU S, NAKAJIMA Y, SUGIYAMA Y: Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Ann. Rev. Pharmacol. Toxicol. (1998) 38:461–499.
  • IWATSUBO T, HIROTA N, OOIE T et al. : Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol. Ther. (1997) 73:147–171.
  • HOUSTON JB, GALETIN A: Progress towards prediction of human pharmacokinetic parameters from in vitro technologies. Drug Metab. Rev. (2003) 35:393–415.
  • THOMPSON TN: Early ADME in support of drug discovery: the role of metabolic stability. Curr. Drug Metab. (2000) 1:215–241.
  • LAVE T, COASSOLO P, REIGNER B: Prediction of hepatic metabolic clearance based on interspecies allometric scaling techniques and in vitro-in vivo correlations. Clin. Pharmacokinet. (1999) 36:211–231.
  • THOMPSON TN: Optimization of metabolic stability as a goal of modern drug design. Med. Res. Rev. (2001) 21:412–449.
  • KASSEL DB: Applications of highthroughput ADME in drug discovery. Curr. Opin. Chem. Biol. (2004) 8:339–345.
  • JANISZEWSKI JS, ROGERS KJ, WHALEN KM et al. : A high-capacity LC/ MS system for the bioanalysis of samples generated from plate-based metabolic screening. Anal. Chem. (2001) 73:1495–1501.
  • DI L, KERNS EH, HONG Y, KLEINTOP TA, MCCONNELL OJ, HURYN DM: Optimization of a higher throughput microsomal stability screening assay for profiling drug discovery candidates. J. Biomol. Screen. (2003) 8:453–462.
  • DI L, KERNS EH, GAO N et al. : Experimental design on single-time-point high-throughput microsomal stability assay. J. Pharm. Sci. (2004) 93:1537–1544.
  • SINZ MW: Drug metabolism in preclinical development. In: Applications of Pharmacokinetic Principles in Drug Development. R Krishna (Ed.), Kluwer Academic, New York, US (2004):75–132.
  • WRING SA, SILVER IS, SERABJIT-SINGH CJ: Automated quantitative and qualitative analysis of metabolic stability: a process for compound selection during drug discovery. Methods Enzymol. (2002) 357:285–295.
  • MCGINNITY DF, SOARS MG, URBANOWICZ RA, RILEY RJ: Evaluation of fresh and cryopreserved hepatocytes as in vitro drug metabolism tools for the prediction of metabolic clearance. Drug Metab. Dispos. (2004) 32:1247–1253.
  • NARITOMI Y, TERASHITA S, KAGAYAMA A, SUGIYAMA Y: Utility of hepatocytes in predicting drug metabolism: comparison of hepatic intrinsic clearance in rats and humans in vivo and in vitro. Drug Metab. Dispos. (2003) 31:580–588.
  • SHIBATA Y, TAKAHASHI H, ISHII Y: A convenient in vitro screening method for predicting in vivo metabolic clearance using isolated hepatocytes suspended in serum. Drug Metab. Dispos. (2000) 28:1518–1523.
  • EDDERSHAW PJ, BERESFORD AP, BAYLISS MK: ADME/PK as part of a rational approach to drug discovery. Drug Discov. Today (2000) 9:409–414.
  • NARITOMI Y, TERASHITA S, KIMURA S, SUZUKI A, KAGAYAMA A, SUGIYAMA Y: Prediction of human hepatic clearance from in vivo animal experiments and in vitro metabolic studies with liver microsomes from animals and humans. Drug Metab. Dispos. (2001) 29:1316–1324.
  • BACHMANN K, BYERS J, GHOSH R: Prediction of in vivo hepatic clearance from in vitro data using cryopreserved human hepatocytes. Xenobiotica (2003) 33:475–483.
  • LAVE T, DUPIN S, SCHMITT C et al. : The use of human hepatocytes to select compounds based on their expected hepatic extraction ratios in humans. Pharm. Res. (1997) 14:152–155.
  • LAU YY, CHEN Y-H, LIU T-T et al. : Evaluation of a novel in vitro Caco-2 hepatocyte hybrid system for predicting in vivo oral bioavailability. Drug Metab. Dispos. (2004) 32:937–942.
  • LAU YY, KRISHNA G, YUMIBE NP et al. : The use of in vitro metabolic stability for rapid selection of compounds in early discovery based on their expected hepatic extraction ratios. Pharm. Res. (2002) 19:1606–1610.
  • HEWITT NJ, BUHRING K-U, DASENBROCK J, HAUNSCHILD J, LADSTETTER B, UTESCH D: Studies comparing in vivo: invitro metabolism of three pharmaceutical compounds in rat, dog, monkey and human using cryopreserved hepatocytes, microsomes and collagen gell immobilized hepatocyte cultures. Drug Metab. Dispos. (2001) 29:1042–1050.
  • SOARS MG, BURCHELL B, RILEY RJ: In vitro analysis of human drug glucuronidation and prediction of in vivo metabolic clearance. J. Pharmacol. Exp. Ther. (2002) 301:382–390.
  • ZUEGGE J, SCHNEIDER G, COASSOLO P, LAVE T: Prediction of hepatic metabolic clearance: comparison and assessment of prediction models. Clin. Pharmacokinet. (2001) 40:553–563.
  • WILSON ZE, ROSTAMI-HODJEGAN A, BURN JL et al. : Inter-individual variability in levels of human microsomal protein and hepatocellularity per gram of liver. Br. J. Clin. Pharmacol. (2003) 56:433–440.
  • SHIMADA T, YAMAZAKI H, MIMURA M, INUI Y, GUENGERICH FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Exp. Ther. (1994) 270:414–423.
  • JONES HM, HOUSTON JB: Substrate depletion approach for determining in vitro metabolic clearance: time dependencies in hepatocyte and microsomal incubations. Drug Metab. Dispos. (2004) 32:973–982.
  • KALVASS JC, TESS DA, GIRAGOSSIAN C, LINHARES MC, MAURER TS: Influence of microsomal concentration on apparent intrinsic clearance: implications for scaling in vitro data. Drug Metab. Dispos. (2001) 29:1332–1336.
  • OBACH RS: Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro half-life approach and nonspecific binding to microsomes. Drug Metab. Dispos. (1999) 27:1350–1359.
  • YIN H, TRAN P, GREENBERG GE, FISCHER V: Methanol solvent may cause increased apparent metabolic instability in in vitro assays. Drug Metab. Dispos. (2001) 29:185–193.
  • UCHAIPICHAT V, MACKENZIE PI, GUO X-H et al. : Human UDPglucuronosyltransferases: isoform selectivity and kinetics of 4-methylumbelliferone and 1-naphthol glucuronidation, effects of organic solvents, and inhibition by diclofenac and probenecid. Drug Metab. Dispos. (2004) 32:413–423.
  • MAHMOOD I: Prediction of clearance in humans from in vitro human liver microsomes and allometric scaling. A comparative study of the two approaches. Drug Metabol. Drug Interact. (2002) 19:49–64.
  • ANDERSSON TB, SJOBERG H, HOFFMAN SJ et al. : An assessment of human liver-derived in vitro systems to predict the in vivo metabolism and clearance of almokalant. Drug Metab. Dispos. (2001) 29:712–720.
  • ANDERSSON TB, BREDBERG E, ERICSSON H, SJOBERG H: An evaluation of the in vitro metabolism data for predicting the clearance and drug-drug interaction potential of CYP2C9 substrates. Drug Metab. Dispos. (2004) 32:715–721.
  • CLARK SE, JEFFERY P: Utility of metabolic stability screening: comparison of in vitro and in vivo clearance. Xenobiotica (2001) 31:591–598.
  • MASIMIREMBWA CM, BREDBERG U, ANDERSSON TB: Metabolic stability for drug discovery and development. Clin. Pharmacokinet. (2003) 42:515–528.
  • NAGILLA R, FRANK KA, JOLIVETTE LJ, WARD KW: Investigation of the utility of published in vitro intrinsic clearance data for prediction of in vivo clearance. J. Pharmacol. Toxicol. Methods (2005) (In Press).
  • YEO KR, HOWGATE EM, TUCKER GT, ROSTAMI-HODJEGAN A: Letter to the editor: predicting the clearance of CYP2C9 substrates. Drug Metab. Dispos. (2004) 32:1522.
  • ANDERSSON TB, BREDBERG E, ERICSSON H, SJOBERG H: Response: predicting the clearance of CYP2C9 substrates. Drug Metab. Dispos. (2004) 32:1523.
  • JULIANO RL, LING V: A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochimica et Biophysica Acta (1976) 455:152–162.
  • LIN JH, YAMAZAKI M: Role of Pglycoprotein in pharmacokinetics. Clin. Pharmacokinet. (2003) 42:59–98.
  • MIZUNO N, NIWA T, YOTSUMOTO Y, SUGIYAMA Y: Impact of drug transporter studies on drug discovery and development. Pharmacol. Rev. (2003) 55:425–461.
  • CHANDRA P, BROUWER KLR: The complexities of hepatic drug transport: current knowledge and emerging concepts. Pharm. Res. (2004) 21:719–735.
  • DIETRICH CG, GEIER A, OUDE ELFERINK RPJ: ABC of oral bioavailability: transporters as gatekeepers in the gut. Gut (2003) 52:1788–1795.
  • CHAN LMS, LOWES S, HIRST BH: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. (2004) 21:25–51.
  • KUSUHARA H, SUGIYAMA Y: Efflux transporter systems for organic anions and cations and the blood-CSF barrier. Adv. Drug Deliv. Rev. (2004) 56:1741–1763.
  • DRESSER MJ, LEABMAN MK, GIACOMINI KM: Transporters involved in the elimination of drugs in the kidney: organic anion transporters and organic cation transporters. J. Pharm. Sci. (2001) 90:397–421.
  • CHIBA P, ECKER GF: Inhibitors of ABCtype drug efflux pumps: an overview of the current patent situation. Expert Opin. Ther. Patents (2004) 14:499–508.
  • WANG RB, KUO CL, LIEN LL, LIEN EJ: Structure-activity relationship: analyses of P-glycoprotein substrates and inhibitors. J. Clin. Pharm. Ther. (2003) 28:203–228.
  • MAEDA K, KUSUHARA H, SUGIYAMA Y: Transporter database, TPSearch: a web-accessible comprehensive database for research in pharmacokinetics of drugs. Pharm. Res. (2005) 21:2133–2134.
  • CONRAD S, VIERTELHAUS A, ORZECHOWSKI A et al. : Sequencing and tissue distribution of the canine MRP2 gene compared with MRP1 and MDR1. Toxicology (2001) 156:81–91.
  • NINOMIYA M, ITO K, HORIE T: Functional analysis of dog multidrug resistance-associated protein 2 (Mrp2) in comparison with rat Mrp2. Drug Metab. Dispos. (2005) 33:225–232.
  • SCHRENK D, GANT TW, PREISEGGER K-H, SILVERMAN JA, MARINO PA, THORGEIRSSON SS: Induction of multi-drug resistance gene expression during cholestasis in rats and nonhuman primates. Hepatology (1992) 17:854–860.
  • KAUFFMANN H-M, KEPPLER D, GANT TW, SCHRENK D: Induction of hepatic mrp2 (cmrp/cmoat) gene expression in nonhuman primates treated with rifampicin or tamoxifen. Arch. Toxicol. (1998) 72:763–768.
  • GANT TW, O’CONNOR CK, CORBITT R, THORGEIRSSON U, THORGEIRSSON SS: In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys. Toxicol. Appl. Pharmacol. (1995) 133:269–276.
  • GODINOT N, IVERSEN PW, TABAS L et al. : Cloning and functional characterization of the multidrug resistanceassociated protein (MRP1/ABCC1) from the cynomolgus monkey. Mol. Cancer Ther. (2003) 2:307–316.
  • KUMAR S, KWEI GY, POON GK et al. : Pharmacokinetics and interactions of a novel antagonist of chemokine receptor 5 (CCR5) with ritonavir in rats and monkeys: role of CYP3A and P-glycoprotein. J. Pharmacol. Exp. Ther. (2003) 304:1161–1171.
  • WARD KW, AZZARANO LM: Preclinical pharmacokinetic properties of the P-glycoprotein inhibitor GF120918A (HCl salt of GF120918, 9,10-dihydro-5-methoxy-9-oxo-N-(4-[2-(1,2,3,4-tetrahydro-6,7- dimethoxy-2-isoquinolinyl)ethyl]phenyl)-4- acridine-carboxamide) in the mouse, rat, dog and monkey. J. Pharmacol. Exp. Ther. (2004) 310:703–709.
  • CHIOU WL, CHUNG SM, WU TC, MA C: A comprehensive account on the role of efflux transporters in the gastrointestinal absorption of 13 commonly used substrate drugs in humans. Int. J. Clin. Pharmacol. Ther. (2001) 39:93–101.
  • LIN JH, YAMAZAKI M: Clinical relevance of P-glycoprotein in drug therapy. Drug Metab. Rev. (2003) 35:417–454.
  • LIN JH: How significant is the role of P-glycoprotein in drug absorption and brain uptake? Drugs of Today (2004) 40:5–22.
  • JANSEN PLM, PETERS WH, LAMERS WH: Heriditary chronic conjugated hyperbilirubinemia in mutant rats caused by defective hepatic anion transport. Hepatology (1985) 5:573–579.
  • MIKAMI T, NOZAKI Y, TAGAYA O et al. : The characters of a new mutant in rats with hyperbilirubinuria syndrome. Congenit. Anom. (1986) 26:250–251.
  • XIONG H, TURNER KC, WARD ES, JANSEN PLM, BROUWER KLR: Altered hepatobiliary disposition of acetominophen glucuronide in isolated perfused livers from multidrug resistance-associated protein 2- deficient TR- rats. J. Pharmacol. Exp. Ther. (2000) 295:512–518.
  • AKITA H, SUZUKI H, SUGIYAMA Y: Sinusoidal efflux of taurocholate is enhances in Mrp2-deficient rat liver. Pharm. Res. (2001) 18:1119–1125.
  • OGURO T, KANEKO E, NUMAZAWA S et al. : Suppressed expression of phenobarbital-inducible hepatic cytochrome P450s in Eisai-hyperbilirubinuria rats (EHBR). J. Pharmacol. Exp. Ther. (1996) 277:1676–1684.
  • SCHUETZ EG, UMBENHAUER DR, YASUDA K et al. : Altered expression of hepatic cytochromes P450 in mice deficient in one or more mdr1 genes. Mol. Pharmacol. (2000) 57:188–197.
  • HOFFMASTER KA, ZAMEK-GLISZCZYNSKI MJ, POLLACK GM, BROUWER KLR: Hepatobiliary disposition of the metabolically stable opiod peptide [D-Pen2, D-Pen5]-enkephalin (DPDPE): pharmacokinetic consequences of the interplay between multiple transport systems. J. Pharmacol. Exp. Ther. (2004) 311:1203–1210.
  • HOFFMASTER KA, ZAMEK-GLISZCZYNSKI MJ, POLLACK GM, BROUWER KLR: Multiple transport systems mediate the hepatic uptake and biliary excretion of the metabolically stable opiod peptide [Dpenicillamine2,5] enkephalin. Drug Metab. Dispos. (2005) 33:287–293.
  • LIU L, PANG KS: The roles of transporters and enzymes in hepatic drug processing. Drug Metab. Dispos. (2005) 33:1–9.
  • DUFFY JC: Prediction of pharmacokinetic parameters in drug design and toxicology. In: Predicting Chemical Toxicity and Fate. MTD Cronin, DJ Livingstone (Eds), CRC Press, Boca Raton, FL, USA (2004):229–261.
  • LIPINSKI CA, LOMBARDO F, DOMINY BW, FEENEY PJ: Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. (1997) 23:3–25.
  • EKINS S, WALLER CL, SWAAN PW, CRUCIANI G, WRIGHTON SA, WIKEL JH: Progress in predicting human ADME parameters in silico. J. Pharmacol. Toxicol. Methods (2000) 44:251–272.
  • VAN DE WATERBEEMD H, GIFFORD E: ADMET in silico modelling: towards prediction paradise? Nat. Rev. Drug Discov. (2003) 2:192–204.
  • VAN DE WATERBEEMD H, DE GROOT M: Can the internet help to meet the challenges in ADME and e-ADME? SAR QSAR Environ. Res. (2002) 13:391–401.
  • PARROTT N, LAVE T: Prediction of intestinal absorption: comparative assessment of GASTROPLUS and IDEA. Eur. J. Pharm. Sci. (2002) 17:51–61.
  • BOOBIS AR, GUNDERT-REMY U, KREMERS P, MACHERAS P, PELKONEN O: In silico prediction of ADME and pharmacokinetics: report of an expert meeting organised by COST B15. Eur. J. Pharm. Sci. (2002) 17:183–193.
  • STOUCH TR, KENYON JR, JOHNSON SR, CHEN X-Q, DOWEYKO A, LI Y: In silico ADME/tox: why models fail. J. Comput. Aided Mol. Des. (2003) 17:83–92.
  • PENZOTTI JE, LANDRUM GA, PUTTA S: Building predictive ADMET models for early decisions in drug discovery. Curr. Opin. Drug Discov. Devel. (2004) 7:49–61.
  • BERESFORD AP, SEGALL M, TARBIT MH: In silico prediction of ADME properties: are we making progress? Curr. Opin. Drug Discov. Devel. (2004) 7:36–42.
  • HANSCH C, LEO A, MEKAPATI SB, KURUP A: QSAR and ADME. Bioorg. Med. Chem. (2004) 12:3391–3400.
  • VEBER DF, JOHNSON SR, CHENG H-Y, SMITH BR, WARD KW, KOPPLE KD: Molecular properties that influence the oral bioavailability of drug candidates. J. Med. Chem. (2002) 45:2615–2623.
  • WAJIMA T, FUKUMURA K, YANO Y, OGUMA T: Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: oral clearance. J. Pharm. Sci. (2003) 92:2427–2440.
  • LU JJ, CRIMIN K, GOODWIN JT et al. : Influence of molecular flexibility and polar surface area metrics on oral bioavailability in the rat. J. Med. Chem. (2004) 47:6104–6107.
  • SCHNEIDER G, COASSOLO P, LAVE T: Combining in vitro and in vivo pharmacokinetic data for prediction of hepatic drug clearance in humans by artificial neural networks and multivariate statistical techniques. J. Med. Chem. (1999) 42:5072–5076.
  • NORRIS DA, LEESMAN GD, SINKO PJ, GRASS GM: Development of predictive pharmacokinetic simulation models for drug discovery. J. Control. Release (2000) 65:55–62.
  • HILL AP, HYDE RM, ROBERTSON AD, WOOLLARD PM, GLEN RC, MARTIN GR: Oral delivery of 5-HT1D receptor agonists: towards the discovery of 311C90, a novel anti-migraine agent. Headache (1994) 34:308.
  • JOLIVETTE LJ, WARD KW: Extrapolation of human pharmacokinetic parameters from rat, dog and monkey data: molecular properties associated with extrapolative success or failure. J. Pharm. Sci. (2005) 94:1467–1483.
  • KIRKPATRICK P: Bridging the divide. Nat. Rev. Drug Discov. (2005) 4:175.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.